Lilly

Eli Lilly Joins Lawsuit to Defend Drug Patent Against Compounding Pharmacies Amid FDA Regulatory Dispute

by

Washington, D.C. — Pharmaceutical giant Eli Lilly has entered the legal fray by filing a motion on January 1 to join a lawsuit challenging the U.S. Food and Drug Administration’s (FDA) decision regarding the manufacturing of generic versions of GLP-1 drugs, such as those Lilly markets under the names Mounjaro and Zepbound. The company asserts significant stakes in the ongoing legal battle over whether compounding pharmacies may continue creating generics previously necessitated by drug shortages. The initial lawsuit was launched in October by the Outsourcing Facilities Association and FarmaKeio Custom Compounding, a Texas-based compounding pharmacy. … Read more

Lilly Seeks Court Action Against Compounded Copies of Its Popular Weight-Loss Medications

by

Indianapolis-based pharmaceutical giant Eli Lilly and Co. has requested to join a lawsuit targeting manufacturers of compounded versions of its popular weight-loss drugs. The company alleges that these compounded versions might pose safety risks and infringe on its intellectual property rights. This legal move comes as the U.S. weight-loss drug market experiences significant growth, driven by increasing awareness and consumer demand for effective obesity treatments. The lawsuit, originally filed by the U.S. Department of Justice, seeks to halt the production and distribution of unauthorized compounded versions of drugs similar to Lilly’s FDA-approved offerings, including Mounjaro … Read more

Pharmaceutical Company PDL BioPharma Files Lawsuit Against Eli Lilly and Company Over Alzheimer’s Treatment Compensation

by

INDIANAPOLIS, IN — Nevada-based company PDL BioPharma, Inc. has filed a lawsuit against Eli Lilly and Company in the U.S. District Court for the Southern District of Indiana. PDL alleges that Eli Lilly used its technology to develop an Alzheimer’s disease treatment without compensating PDL. According to the lawsuit filed on December 21, 2023, PDL claims that Eli Lilly used its antibody humanization technology to create donanemab, a treatment for Alzheimer’s. Donanemab is expected to receive FDA approval in the first quarter of 2024. The lawsuit refers to a 2000 agreement between Eli Lilly and … Read more